Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables: 2015-2019

Historic Notes Payables for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Mar 2019 value amounting to $18,000.

  • Lineage Cell Therapeutics' Notes Payables fell 85.00% to $18,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $18,000, marking a year-over-year decrease of 85.00%. This contributed to the annual value of $70,000 for FY2018, which is 53.95% down from last year.
  • According to the latest figures from Q1 2019, Lineage Cell Therapeutics' Notes Payables is $18,000, which was down 74.29% from $70,000 recorded in Q4 2018.
  • Over the past 5 years, Lineage Cell Therapeutics' Notes Payables peaked at $2.6 million during Q2 2017, and registered a low of $18,000 during Q1 2019.
  • Moreover, its 3-year median value for Notes Payables was $120,000 (2018), whereas its average is $477,889.
  • Its Notes Payables has fluctuated over the past 5 years, first surged by 2,589.47% in 2017, then crashed by 95.30% in 2018.
  • Lineage Cell Therapeutics' Notes Payables (Quarterly) stood at $95,000 in 2015, then skyrocketed by 776.84% to $833,000 in 2016, then slumped by 81.75% to $152,000 in 2017, then tumbled by 53.95% to $70,000 in 2018, then slumped by 85.00% to $18,000 in 2019.
  • Its last three reported values are $18,000 in Q1 2019, $70,000 for Q4 2018, and $70,000 during Q3 2018.